BBH holdings
All 27 positions of VanEck Biotech ETF.
Positions
27
Top 10 weight
72.8%
Effective holdings
13.5
1 / sum of squared weights
In stocks
100.3%
In bonds
0.0%
Outside the US
2.8%
Asset mix
Sectors
100% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | AMGNAmgen Inc | Equity | 15.92% | $75M | 184,506 | US |
| 2 | GILDGilead Sciences Inc | Equity | 13.58% | $64M | 435,801 | US |
| 3 | VRTXVertex Pharmaceuticals Inc | Equity | 8.26% | $39M | 77,463 | US |
| 4 | REGNRegeneron Pharmaceuticals Inc | Equity | 6.62% | $31M | 42,244 | US |
| 5 | MRNAModerna, Inc. Common Stock | Equity | 6.47% | $31M | 155,157 | US |
| 6 | NTRANatera, Inc. Common Stock | Equity | 5.27% | $25M | 63,701 | US |
| 7 | IQVIQVIA Holdings Inc. | Equity | 4.49% | $21M | 81,878 | US |
| 8 | ARGXargenx SE American Depositary Shares | Equity | 4.09% | $19M | 23,582 | |
| 9 | ILMNIllumina Inc | Equity | 4.08% | $19M | 72,823 | US |
| 10 | RVMDRevolution Medicines, Inc. Common Stock | Equity | 4.04% | $19M | 101,314 | US |
| 11 | GHGuardant Health, Inc. Common Stock | Equity | 2.91% | $14M | 83,072 | US |
| 12 | BIIBBiogen Inc. Common Stock | Equity | 2.76% | $13M | 59,559 | US |
| 13 | ONCBeOne Medicines Ltd. American Depositary Shares | Equity | 2.75% | $13M | 37,142 | |
| 14 | ALNYAlnylam Pharmaceuticals, Inc. | Equity | 2.56% | $12M | 53,938 | US |
| 15 | UTHRUnited Therapeutics Corp | Equity | 2.30% | $11M | 20,376 | US |
| 16 | INCYIncyte Genomics Inc | Equity | 2.16% | $10M | 90,460 | US |
| 17 | INSMInsmed, Inc. | Equity | 1.94% | $9.2M | 91,172 | US |
| 18 | CRLCharles River Laboratories International, Inc. | Equity | 1.58% | $7.5M | 25,085 | US |
| 19 | BNTXBioNTech SE American Depositary Share | Equity | 1.55% | $7.3M | 79,560 | DE |
| 20 | NBIXNeurocrine Biosciences Inc | Equity | 1.44% | $6.8M | 48,291 | US |
| 21 | ICLRIcon Plc | Equity | 1.26% | $5.9M | 36,099 | IE |
| 22 | TECHBio-Techne Corp. | Equity | 1.21% | $5.7M | 79,016 | US |
| 23 | BMRNBioMarin Pharmaceuticals Inc | Equity | 1.07% | $5.0M | 91,962 | US |
| 24 | QGENQIAGEN N.V. | Equity | 0.98% | $4.6M | 104,200 | |
| 25 | TEMTempus AI, Inc. Class A Common Stock | Equity | 0.98% | $4.6M | 66,912 | US |
| 26 | Cash | Cash | 0.00% | −$3K | -3,182 | |
| 27 | Other/Cash | Cash | -0.28% | −$1.3M | — |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Decrease | UTHRUnited Therapeutics Corp | 3.81% | 2.83% | −15.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ARGXArgenx SE | 5.28% | 4.97% | −22.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | MRNAModerna Inc | 3.10% | 3.36% | −17.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | BNTXBioNTech SE | 2.15% | 1.94% | −10.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | TECHBio-Techne Corp | 1.35% | 1.54% | −11.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | NBIXNeurocrine Biosciences Inc | 1.94% | 2.08% | −12.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | BIIBBiogen Inc | 3.72% | 3.63% | −13.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | TEMTempus AI Inc | 0.93% | 0.98% | −13.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | RVMDRevolution Medicines Inc | — | 2.86% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | EXASExact Sciences Corp | 2.20% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | MRNAModerna Inc | 1.59% | 3.10% | +16.8% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | RGENRepligen Corp | 1.31% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | QIAGEN NV | 1.27% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ICON PLC | 2.46% | 1.27% | −12.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | QIAGEN NV | — | 1.15% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | BIIBBiogen Inc | 3.16% | 3.72% | +16.5% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ARGXArgenx SE | 4.72% | 5.28% | +32.5% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | INSMInsmed Inc | 4.12% | 4.59% | +22.0% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | BNTXBioNTech SE | 1.82% | 2.15% | +30.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ALNYAlnylam Pharmaceuticals Inc | 4.42% | 4.11% | +14.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | INCYIncyte Corp | 1.96% | 2.25% | +24.1% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | IQVIQVIA Holdings Inc | 4.55% | 4.30% | +28.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | BMRNBioMarin Pharmaceutical Inc | 1.22% | 1.39% | +23.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | TEMTempus AI Inc | 1.09% | 0.93% | +14.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | TECHBio-Techne Corp | 1.32% | 1.35% | +18.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | NBIXNeurocrine Biosciences Inc | 1.95% | 1.94% | +10.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.